<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2ffa08e2-0405-47bb-e063-6294a90a4fe0"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <br/>
      <content styleCode="bold">These highlights do not include all the information needed to use LEVOFLOXACIN OPHTHALMIC SOLUTION safely and effectively. See full prescribing information for LEVOFLOXACIN OPHTHALMIC SOLUTION. </content>
      <br/>
      <br/>
      <content styleCode="bold">LEVOFLOXACIN ophthalmic solution 0.5%
  <br/>
Sterile topical ophthalmic solution 
 </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1996</content>
   </title>
   <effectiveTime value="20250310"/>
   <setId root="f2eb9444-333d-4b05-8cf3-2e6690a2bf99"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="051627256"/>
            <name>Advagen Pharma Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="675627643"/>
                        <name>CIRON DRUGS AND PHARMACEUTICALS PVT LTD</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72888-142" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="72888-142" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2ffa171d-2b9a-6b40-e063-6294a90a3e16"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250310"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72888-142" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>LEVOFLOXACIN</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>LEVOFLOXACIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6GNT3Y5LMF" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LEVOFLOXACIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="RIX4E89Y14" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LEVOFLOXACIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="72888-142-22" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220222"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA078282" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220222"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>Light yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="sec_6875796988">
               <id root="2ffa08e2-0406-47bb-e063-6294a90a4fe0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Levofloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Gram-positive bacteria</content>
                  </paragraph>
                  <paragraph>Corynebacterium
 
  <content styleCode="italics">species</content>*

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Staphylococcus aureus</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Staphylococcus epidermidis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Streptococcus pneumonia</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Streptococcus</content>(Groups C/F)

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Streptococcus</content>(Group G)

 </paragraph>
                  <paragraph>Viridans group streptococci*</paragraph>
                  <paragraph>
                     <content styleCode="underline">Gram-negative bacteria</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Acinetobacter lwoffii *</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Haemophilus influenzae</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Serratia marcescens*</content>
                  </paragraph>
                  <paragraph/>
                  <paragraph>*Efficacy for this organism was studied in fewer than 10 infections</paragraph>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levofloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gram-positive bacteria:</content>
                        </paragraph>
                        <paragraph>Corynebacterium
 
    <content styleCode="italics">species</content>*

   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus epidermidis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pneumonia</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus</content>(Groups C/F)

   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus</content>(Group G)

   </paragraph>
                        <paragraph>Viridans group streptococci*</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">Gram-negative bacteria:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Acinetobacter lwoffii *</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Serratia marcescens*</content>
                        </paragraph>
                        <paragraph>*Efficacy for this organism was studied in fewer than 10 infections (
 
    <linkHtml href="#sec_6875796988">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="sec_7776707581">
               <id root="2ffa08e2-0407-47bb-e063-6294a90a4fe0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Days 1 and 2</content>
                  </paragraph>
                  <paragraph>Instill one to two drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Days 3 through 7</content>
                  </paragraph>
                  <paragraph>Instill one to two drops in the affected eye(s) every 4 hours while awake, up to 4 times per day.</paragraph>
               </text>
               <effectiveTime value="20220222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Day</content>
                           <content styleCode="bold">s 1 and 2:</content>
                        </paragraph>
                        <paragraph>Instill one to two drops in the affected eye(s) every 2 hours while awake, up to 8 times per day.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Day</content>
                           <content styleCode="bold">s 3 through 7:</content>
                        </paragraph>
                        <paragraph>Instill one to two drops in the affected eye(s) every 4 hours while awake, up to 4 times per day. (
 
    <linkHtml href="#sec_7776707581">2</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="sec_8176817683">
               <id root="2ffa08e2-0408-47bb-e063-6294a90a4fe0"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>5 mL white LDPE bottle filled with 5 mL sterile ophthalmic solution of levofloxacin, 0.5%.</paragraph>
               </text>
               <effectiveTime value="20220222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>5 mL white LDPE bottle filled with 5 mL sterile ophthalmic solution of levofloxacin, 0.5% (
 
    <linkHtml href="#sec_8176817683">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="sec_8776818887">
               <id root="2ffa08e2-0409-47bb-e063-6294a90a4fe0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Levofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this medication.</paragraph>
               </text>
               <effectiveTime value="20220222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Levofloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components in this medication. (
 
    <linkHtml href="#sec_8776818887">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="sec_8790766974">
               <id root="2ffa08e2-040a-47bb-e063-6294a90a4fe0"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20220222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Hypersensitivity and anaphylaxis have been reported with systemic use of levofloxacin as well as topical use of other fluoroquinolones, including levofloxacin ophthalmic solution. (
  
     <linkHtml href="#sec_7368728583">5.1</linkHtml>)
 
    </item>
                           <item>Prolonged use may result in the overgrowth of non- susceptible organisms, including fungi. (
  
     <linkHtml href="#sec_7178769081">5.2</linkHtml>)
 
    </item>
                           <item>Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis. (
  
     <linkHtml href="#sec_6575766970">5.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="sec_7368728583">
                     <id root="2ffa08e2-040b-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>In patients receiving systemically administered quinolones, including levofloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema, (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria and itching. If allergic reaction to levofloxacin occurs, discontinue the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered as clinically indicated.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_7178769081">
                     <id root="2ffa08e2-040c-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Growth of Resistant Organisms with Prolonged Use</title>
                     <text>
                        <paragraph>As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_6575766970">
                     <id root="2ffa08e2-040d-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Avoidance of Contact Lens Wear</title>
                     <text>
                        <paragraph>Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.</paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="sec_7769676689">
               <id root="2ffa08e2-040e-47bb-e063-6294a90a4fe0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The most frequently reported adverse reactions in the overall study population were transient decreased vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis and photophobia. These reactions occurred in approximately 1-3% of patients. Other reported reactions occurring in less than 1% of patients included allergic reactions, lid edema, ocular dryness, and ocular itching.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250219"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most frequently reported adverse reactions in the overall study population were transient decreased vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis and photophobia. These reactions occurred in approximately 1 to 3% of patients. Other reported reactions occurring in less than 1% of patients included allergic reactions, lid edema, ocular dryness, and ocular itching. (
 
    <linkHtml href="#sec_7769676689">6</linkHtml>)

   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Advagen Pharma Ltd, at 866-488-0312 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="sec_8265806583">
               <id root="2ffa08e2-040f-47bb-e063-6294a90a4fe0"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20220222"/>
               <component>
                  <section ID="sec_7790676780">
                     <id root="2ffa08e2-0410-47bb-e063-6294a90a4fe0"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Teratogenic Effects</content>
                        </paragraph>
                        <paragraph>Levofloxacin at oral doses of 810 mg/kg/day in rats caused decreased fetal body weight and increased fetal mortality. No teratogenic effect was observed when rabbits were dosed orally as high as 50 mg/kg/day, at which systemic exposure was approximately 2,250 times that observed at the maximum recommended human ophthalmic dose, or when dosed intravenously as high as 25 mg/kg/day, at which systemic exposure was approximately 1000 times that observed at the maximum recommended human ophthalmic dose.</paragraph>
                        <paragraph/>
                        <paragraph>There are, however, no adequate and well-controlled studies in pregnant women. Levofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_8172797785">
                     <id root="2ffa08e2-0411-47bb-e063-6294a90a4fe0"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Levofloxacin has not been measured in human milk. Based upon data from ofloxacin, it can be presumed that levofloxacin is excreted in human milk. Caution should be exercised when levofloxacin ophthalmic solution is administered to a nursing mother.</paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_7972817583">
                     <id root="2ffa08e2-0412-47bb-e063-6294a90a4fe0"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in children below the age of six years have not been established. Oral administration of systemic quinolones has been shown to cause arthropathy in immature animals. There is no evidence that the ophthalmic administration of levofloxacin has any effect on weight bearing joints.</paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_8272667276">
                     <id root="2ffa08e2-0413-47bb-e063-6294a90a4fe0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="sec_9082827389">
               <id root="2ffa08e2-0414-47bb-e063-6294a90a4fe0"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Levofloxacin Ophthalmic Solution, 0.5% is a sterile topical ophthalmic solution. Levofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of Gram-positive and Gram-negative ocular pathogens. Levofloxacin is a fluorinated 4-quinolone containing a six-member (pyridobenzoxazine) ring from positions 1 to 8 of the basic ring structure. Levofloxacin is the pure (-)-(S)-enantiomer of the racemic drug substance, ofloxacin. It is more soluble in water at neutral pH than ofloxacin.</paragraph>
                  <renderMultiMedia referencedObject="MM0"/>
                  <paragraph>Chemical Name: (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido [1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate.</paragraph>
                  <paragraph>Levofloxacin (hemihydrate) is a light yellow powder.</paragraph>
                  <paragraph>Each mL of levofloxacin ophthalmic solution, 0.5% contains 5.12 mg of levofloxacin hemihydrate equivalent to 5 mg levofloxacin.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contains</content>
                     <br/>  Levofloxacin 5 mg equivalent to 5.12 mg levofloxacin hemihydrate with benzalkonium chloride 0.005%, sodium chloride, water for injection, hydrochloric acid and/or sodium hydroxide (to adjust pH).

 </paragraph>
                  <paragraph>Levofloxacin ophthalmic solution, 0.5% is isotonic and formulated at pH 6.0-6.8 with an osmolality between 285-315 mOsm/kg.</paragraph>
               </text>
               <effectiveTime value="20220222"/>
               <component>
                  <observationMedia ID="MM0">
                     <text>Levofloxacin Ophthalmic Solution, 0.5% is a sterile topical ophthalmic solution. Levofloxacin is a fluoroquinolone antibacterial active against a broad spectrum of Gram-positive and Gram-negative ocul</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-ophthalmic-solution-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="sec_7875728075">
               <id root="2ffa08e2-0415-47bb-e063-6294a90a4fe0"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text/>
               <effectiveTime value="20220222"/>
               <component>
                  <section ID="sec_7671676782">
                     <id root="2ffa08e2-0416-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Levofloxacin is a member of the fluoroquinolone class of anti-infective drugs.
 
  <content styleCode="italics">(See
  
   <linkHtml href="#sec_8185687082">12.4 Microbiology</linkHtml>)
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_8972866782">
                     <id root="2ffa08e2-0417-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.2 Pharmacokinetics</title>
                     <text>
                        <paragraph>Levofloxacin concentration in plasma was measured in 15 healthy adult volunteers at various time points during a 15-day course of treatment with levofloxacin ophthalmic solution. The mean levofloxacin concentration in plasma 1 hour postdose, ranged from 0.86 ng/mL on Day 1 to 2.05 ng/mL on Day 15. The highest maximum mean levofloxacin concentration of 2.25 ng/mL was measured on Day 4 following 2 days of dosing every 2 hours for a total of 8 doses per day. Maximum mean levofloxacin concentrations increased from 0.94 ng/mL on Day 1 to 2.15 ng/mL on Day 15, which is more than 1,000 times lower than those reported after standard oral doses of levofloxacin.</paragraph>
                        <paragraph/>
                        <paragraph>Levofloxacin concentration in tears was measured in 30 healthy adult volunteers at various time points following instillation of a single drop of levofloxacin ophthalmic solution. Mean levofloxacin concentrations in tears ranged from 34.9 to 221.1 mcg/mL during the 60-minute period following the single dose. The mean tear concentrations measured 4 and 6 hours postdose were 17.0 and 6.6 mcg/mL. The clinical significance of these concentrations is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_8185687082">
                     <id root="2ffa08e2-0418-47bb-e063-6294a90a4fe0"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.3 Microbiology</title>
                     <text>
                        <paragraph>Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves the inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair, and recombination.</paragraph>
                        <paragraph/>
                        <paragraph>Levofloxacin has
 
  <content styleCode="italics">in vitro</content>activity against a wide range of Gram-negative and Gram-positive microorganisms and is often bactericidal at concentrations equal to or slightly greater than inhibitory concentrations.

 </paragraph>
                        <paragraph/>
                        <paragraph>Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from β- lactam antibiotics and aminoglycosides, and therefore may be active against bacteria resistant to β- lactam antibiotics and aminoglycosides. Additionally, β-lactam antibiotics and aminoglycosides may be active against bacteria resistant to levofloxacin.</paragraph>
                        <paragraph>Resistance to levofloxacin due to spontaneous mutation
 
  <content styleCode="italics">i</content>
                           <content styleCode="italics">n vitro</content>is a rare occurrence (range: 10
 
  <sup>-9</sup>to 10
 
  <sup>-10</sup>)

 </paragraph>
                        <paragraph/>
                        <paragraph>Levofloxacin has been shown to be active against most strains of the following microorganisms, both
 
  <content styleCode="italics">in vitro</content>and in clinical infections as described in the INDICATIONS AND USAGE section:

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Aerobic gram-positive microorganisms</content>
                        </paragraph>
                        <paragraph>Corynebacterium species*</paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus epidermidis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pneumonia</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus</content>(Groups C/F)

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus</content>(Group G)

 </paragraph>
                        <paragraph>Viridans group streptococci*</paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Aerobic gram-negative microorganisms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Acinetobacter lwoffii*</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Serratia marcescens*</content>
                        </paragraph>
                        <paragraph>*Efficacy for this organism was studied in fewer than 10 infections.</paragraph>
                        <paragraph/>
                        <paragraph>The following
 
  <content styleCode="italics">i</content>
                           <content styleCode="italics">n vitro</content>data are also available, but their clinical significance in ophthalmic infections is unknown. The safety and effectiveness of levofloxacin in treating ophthalmological infections due to these microorganisms have not been established in adequate and well- controlled trials.

 </paragraph>
                        <paragraph/>
                        <paragraph>These organisms are considered susceptible when evaluated using systemic breakpoints. However, a correlation between the
 
  <content styleCode="italics">in vitro</content>systemic breakpoint and ophthalmological efficacy has not been established. The list of organisms is provided as guidance only in assessing the potential treatment of conjunctival infections. Levofloxacin exhibits
 
  <content styleCode="italics">in vitro</content>minimal inhibitory concentrations (MICs) of 2 mcg/mL or less (systemic susceptible breakpoint) against most (≥90%) strains of the following ocular pathogens:

 </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Aerobicgram-positive microorganisms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Enterococcus faecalis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus saprophyticus</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus agalactiae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pyogenes</content>
                        </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="underline">Aerobic gram-negative microorganisms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Acinetobacter anitratus</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Acinetobacter baumannii</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Citrobacter koseri</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Citrobacter freundii</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Enterobacter aerogenes</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Enterobacter agglomerans</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Enterobacter cloacae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Escherichia coli</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus parainfluenzae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella oxytoca</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella pneumonia</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Legionella pneumophila</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Moraxella catarrhalis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Morganella morganii</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Neisseria gonorrhoeae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Proteus mirabilis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Proteus vulgaris</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Providencia rettgeri</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Providencia stuartii</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pseudomonas aeruginosa</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pseudomonas fluorescens</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="sec_8466716774">
               <id root="2ffa08e2-0419-47bb-e063-6294a90a4fe0"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text/>
               <effectiveTime value="20220222"/>
               <component>
                  <section ID="sec_6771838887">
                     <id root="2ffa08e2-041a-47bb-e063-6294a90a4fe0"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>In a long term carcinogenicity study in rats, levofloxacin exhibited no carcinogenic or tumorigenic potential following daily dietary administration for 2 years at doses up to 100 mg/kg/day, corresponding to plasma levels that were 1235 times the maximum clinical exposure, based on C
 
  <sub>max</sub>.

 </paragraph>
                        <paragraph/>
                        <paragraph>Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay (
 
  <content styleCode="italics">S. typhimurium</content>and
 
  <content styleCode="italics">E</content>
                           <content styleCode="italics">. coli</content>), CHO/HGPRT forward mutation assay, mouse micronucleus test, mouse dominant lethal test, rat unscheduled DNA synthesis assay, and the
 
  <content styleCode="italics">in vivo</content>mouse sister chromatid exchange assay. It was positive in the
 
  <content styleCode="italics">in vitro</content>chromosomal aberration (CHL cell line) and
 
  <content styleCode="italics">in vitro</content>sister chromatid exchange (CHL/IU cell line) assays. Levofloxacin caused no impairment of fertility or reproduction in rats at oral doses as high as 360 mg/kg/day, at which systemic exposure was estimated to be 23,000 times that at the maximum recommended human ophthalmic dose.

 </paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="sec_7779858472">
               <id root="2ffa08e2-041b-47bb-e063-6294a90a4fe0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In randomized, double-masked, multicenter controlled clinical trials where patients were dosed for 5 days, Levofloxacin ophthalmic® demonstrated clinical cures in 79% of patients treated for bacterial conjunctivitis on the final study visit day (day 6 to10). Microbial outcomes for the same clinical trials demonstrated an eradication rate for presumed pathogens of 90%.</paragraph>
               </text>
               <effectiveTime value="20220222"/>
            </section>
         </component>
         <component>
            <section ID="sec_7884748680">
               <id root="2ffa08e2-041c-47bb-e063-6294a90a4fe0"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE HANDLING</title>
               <text>
                  <paragraph>Levofloxacin Ophthalmic Solution, 0.5% is a clear light yellow solution supplied in a white LDPE bottle with translucent LDPE nozzle and tan coloured HDPE cap in the following size:</paragraph>
                  <paragraph/>
                  <paragraph>5 mL filled in 5 mL bottle – NDC 72888-142-22</paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Storage:</content>
                  </paragraph>
                  <paragraph>Store at 20º to 25°C (68º to 77°F) [See USP Controlled Room Temperature].</paragraph>
               </text>
               <effectiveTime value="20220222"/>
            </section>
         </component>
         <component>
            <section ID="sec_6680836867">
               <id root="2ffa08e2-041d-47bb-e063-6294a90a4fe0"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text/>
               <effectiveTime value="20250219"/>
               <component>
                  <section ID="sec_6967678967">
                     <id root="2ffa08e2-041e-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Avoid Contamination of the Product</title>
                     <text>
                        <paragraph>Advise patients to avoid contaminating the applicator tip with material from the eye, finger, or other source.</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_6565757876">
                     <id root="2ffa08e2-041f-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2 Avoid Contact Lens Wear</title>
                     <text>
                        <paragraph>Advise patients not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20220222"/>
                  </section>
               </component>
               <component>
                  <section ID="sec_8580766870">
                     <id root="2ffa08e2-0420-47bb-e063-6294a90a4fe0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Systemically administered quinolones, including levofloxacin, have been associated with hypersensitivity reactions, even following a single dose. Advise patients to discontinue use immediately and contact their physician at the first sign of a rash or allergic reaction.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Distributed by:</content>
                        </paragraph>
                        <paragraph>Advagen Pharma Ltd.,</paragraph>
                        <paragraph>East Windsor, NJ 08520, USA</paragraph>
                        <paragraph>Rev. 02/2025</paragraph>
                     </text>
                     <effectiveTime value="20250219"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="sec_6576757386">
               <id root="2ffa08e2-0421-47bb-e063-6294a90a4fe0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Levofloxacin Ophthalmic Solution, 0.5% Sterile Ophthalmic Solution - NDC 72888-142-22 - 5 mL Carton Label</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>
                     <content styleCode="bold">Levofloxacin Ophthalmic Solution, 0.5% Sterile Ophthalmic Solution - NDC 72888-142-22 - 5 mL Container Label</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20220222"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Levofloxacin Ophthalmic Solution, 0.5% Sterile Ophthalmic Solution - NDC 72888-142-22 - 5 mL Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-ophthalmic-solution-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Levofloxacin Ophthalmic Solution, 0.5% Sterile Ophthalmic Solution - NDC 72888-142-22 - 5 mL Container Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="levofloxacin-ophthalmic-solution-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>